The possibility of combining more than two biomarkers has also been considered by Franklin and colleagues [48], who evaluated four stroma-derived biomarkers—collagen 4, endostatin, tenascin C, and osteopontin—and 4 conventional markers—cancer antigens CA 19.9 and CA 125, CEA (carcinoembryonic antigen), and TPS (tissue polypeptide-specific antigen). This evidence concerns the gene COL18A1 and cancer.